Boehringer Ingelheim announced that the U.S. FDA has approved a supplemental New Drug Application (sNDA) for Gilotrif® (afatinib) tablets for the treatment of patients with advanced squamous cell carcinoma of the lung whose disease has progressed after treatment with platinum-based chemotherapy.  This approval provides a new second-line treatment option for patients with the second largest sub-type
of non-small cell lung cancer (NSCLC), representing about 20-30% of NSCLC cases.  Squamous cell carcinoma (SqCC) of the lung is associated with a poor prognosis, limited survival and symptoms like cough and dyspnea. The median overall survival (OS) after diagnosis of advanced SqCC is around one year.